Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
|
|
Agence France Presse (10.21.09) - Monday, October 26, 2009
The study involved 766 participants in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial who had HCV-related bridging fibrosis or cirrhosis on liver biopsy and who failed to respond to peginterferon plus ribavirin. Baseline coffee and tea intake were assessed among patients, who were seen every three months and given liver biopsies at 1.5 years and 3.5 years.
"We observed an inverse association between coffee intake and liver disease progression," wrote Neal D. Freedman of the National Cancer Institute and colleagues. HCV liver disease- related clinical outcomes declined with increased coffee consumption: 11.1/100 person-years for no coffee, 12.1 for less than one cup per day, 8.2 for one to fewer than three cups per day, and 6.3 for three or more cups per day (P- trend=0.0011). Compared with not drinking coffee, relative risks at 95 percent confidence intervals were 1.1 (0.76-1.61) for less than one cup a day; 0.70 (0.48-1.02) for one to fewer than three cups a day; and 0.47 (0.27-0.85) for three or more cups per day.
"In a large prospective study of participants with advanced hepatitis C-related liver disease, regular coffee consumption was associated with lower rates of disease progression," the authors concluded.
Coffee may protect against liver disease by reducing the risk of type-two diabetes, which has been associated with liver disease, or by reducing inflammation, researchers suggested. Caffeine has also previously been found to inhibit liver cancer in rats. Drinking black or green tea, which also contain caffeine, had no association with liver disease progress; however, few study participants consumed tea.
The full report, "Coffee Intake Is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C," was published in Hepatology (2009;doi:10.1002/hep.23162).
091026
AD091834
Copyright © 2009 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.